Moderna Inc. share price resilient despite drop in quarterly revenue and earnings
In this article we review the Moderna results and how the share price has reacted to the news.
Moderna Inc’s quarterly results
Moderna Inc, the biotechnology company focused on messenger ribonucleic acid (mRNA) medicines, has released results for the fiscal quarter ending September 2022, a summary of which is as follows:
Adjusted earnings per share (EPS) of $2.53 for the quarter, consensus estimates from Refinitiv data had expected adjusted EPS of $3.29
Revenue declined by 32.3% to $3.36 billion from a year ago, while estimates from Refinitiv data had expected revenue of $3.53 billion.
Net income of $1.04 billion was recorded over the reporting period
Group results fell short of consensus resulting in a knee-jerk market reaction, whereby the share price fell initially before managing to claw back losses.
The company has seen a decline in its sales of Covid-19 vaccines to weigh on revenue. Write downs pertaining to past shelf life Covid products also dramatically increased the group’s cost of sales, which along with increased research and development expenses as well as a higher effective tax rate pressured earnings relative to the prior year’s comparative reporting period.
How to trade Moderna Inc shares
As of the 3rd of November 2022, a Refinitiv poll of 19 brokers and analysts suggest the stock to be a ‘hold’ at current levels. There are no sell recommendations on the company.
The long-term price target mean of $207.29 suggests the share price of Moderna to currently be trading at a 41% discount to its assumed longer dated fair value.
Most IG clients (82%) with open positions on the stock, as of the 3rd of November 2022, expect the share price to rise in the near term, while 18% of IG clients with open positions on the stock expect the share price of Moderna to fall.
Moderna Inc. – Technical View
The share price of Moderna has recently broken out of the consolidation highlighted by the grey rectangle on our chart. The red arrow highlights the 20-day simple moving average crossing above the 50 day simple moving average, a suggestion that the short to medium term trends are moving from down to up. The price is also now trading above the 200 day simple moving average (blue line), an indication that the longer term down trend may now be broken.
The bullish indications suggest that 158.80 could be the next resistance target from the move, a break of which, confirmed with a close could unlock further gains towards the 179.00 level. Traders who are long might consider using a close below the 142.00 support level as a stop loss indication for the trade.
In summary:
Moderna Inc quarterly revenue and earnings have declined significantly against the prior year’s comparative period
Revenue and EPS for the reporting period both fell short of consensus estimates
Analyst ratings suggest the share price to be a hold at current levels
The majority of IG clients with open positions on the stock expect the price to rise in the near term
The share price has broken out of a near term consolidation with 158.80 the next upside resistance target from the move
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.
